• LAST PRICE
    0.6494
  • TODAY'S CHANGE (%)
    Trending Up0.0515 (8.6135%)
  • Bid / Lots
    0.6425/ 5
  • Ask / Lots
    0.6525/ 4
  • Open / Previous Close
    0.6100 / 0.5979
  • Day Range
    Low 0.6025
    High 0.6625
  • 52 Week Range
    Low 0.5000
    High 4.4500
  • Volume
    300,195
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.5979
TimeVolumeCARA
09:32 ET73450.61
09:34 ET2630.6186
09:36 ET2350.6114
09:48 ET6000.6149
09:52 ET1000.6148
09:57 ET11000.6205
09:59 ET5000.6229
10:03 ET13500.62015
10:08 ET4770.6148
10:12 ET1000.6202
10:14 ET2440.6148
10:15 ET8670.6224
10:19 ET3000.6296
10:21 ET14000.614801
10:26 ET4920.63
10:32 ET3000.6201
10:35 ET1200.625049
10:37 ET2500.6299
10:39 ET49900.63
10:44 ET4150.639005
10:46 ET4000.63005
10:48 ET9500.6399
10:50 ET1000.6201
10:53 ET1000.621
10:55 ET1000.621
11:00 ET1000.638
11:02 ET15850.625
11:06 ET11000.6299
11:09 ET5640.625
11:11 ET13000.629251
11:13 ET1000.625
11:20 ET74950.6313
11:22 ET1700.63783
11:24 ET9240.6321
11:31 ET1000.632
11:44 ET23500.6389
11:45 ET52430.6322
11:49 ET5000.6321
11:54 ET1650.6431
11:56 ET6400.64
12:02 ET11700.6401
12:07 ET5000.6436
12:12 ET3060.6427
12:14 ET51730.65
12:16 ET1360.6555
12:23 ET3000.6518
12:27 ET3110.655
12:32 ET126090.6558
12:34 ET5000.6516
12:38 ET1000.648
12:41 ET3000.648
12:45 ET2000.6436
12:48 ET1000.6436
12:52 ET6300.6403
12:54 ET218790.6599
12:56 ET12840.6599
12:57 ET3580.64825
12:59 ET6300.6549
01:01 ET1000.6513
01:03 ET3170.64797
01:14 ET18390.654815
01:15 ET32490.64
01:17 ET1720.632
01:19 ET76800.6321
01:21 ET2160.632
01:28 ET19500.6358
01:39 ET1000.6321
01:46 ET2000.6453
01:50 ET26990.6441
01:55 ET10000.6406
01:57 ET20010.6321
02:00 ET14580.64
02:04 ET3000.64
02:08 ET52000.632
02:09 ET2000.632
02:11 ET1000.632
02:13 ET1000.632
02:15 ET1000.632
02:18 ET10500.6388
02:20 ET1000.632
02:24 ET2000.632
02:26 ET3990.632
02:27 ET2000.632
02:29 ET51630.64
02:31 ET4190.6431
02:33 ET8000.6459
02:36 ET28300.65
02:40 ET2000.65
02:42 ET1000.645
02:45 ET209030.64665
02:47 ET11000.64
02:49 ET7000.6495
02:51 ET1000.641
02:54 ET8470.6425
02:56 ET3450.6419
02:58 ET8000.64
03:00 ET1000.64
03:02 ET19010.64
03:03 ET3000.64
03:07 ET39000.6406
03:09 ET1000.64
03:12 ET1000.64
03:18 ET16780.645
03:21 ET1000.64
03:23 ET7490.64
03:27 ET1000.64
03:30 ET25750.64
03:32 ET3000.6438
03:36 ET2000.64
03:38 ET12000.64
03:39 ET2000.6425
03:41 ET14890.64
03:43 ET1000.6455
03:48 ET9750.6401
03:52 ET9050.64
03:54 ET90310.643
03:56 ET19220.6429
03:57 ET20390.64295
03:59 ET65300.6494
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCARA
Cara Therapeutics Inc
32.7M
-0.3x
---
United StatesICCC
ImmuCell Corp
34.1M
-8.4x
---
United StatesAADI
Aadi Bioscience Inc
42.6M
-0.7x
---
United StatesSQZB
SQZ Biotechnologies Co
1.3M
0.0x
---
United StatesVDRM
Viaderma Inc
8.3M
0.0x
---
United StatesTSBX
Turnstone Biologics Corp
60.8M
-0.7x
---
As of 2024-05-31

Company Information

Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.

Contact Information

Headquarters
400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
Phone
203-406-3700
Fax
203-567-1510

Executives

Independent Chairman of the Board
Martin Vogelbaum
President, Chief Executive Officer, Director
Christopher Posner
Chief Financial Officer
Ryan Maynard
Chief Compliance Officer, General Counsel, Secretary
Scott Terrillion
Director
Helen Boudreau

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$32.7M
Revenue (TTM)
$16.9M
Shares Outstanding
54.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.78
EPS
$-2.26
Book Value
$1.05
P/E Ratio
-0.3x
Price/Sales (TTM)
1.9
Price/Cash Flow (TTM)
---
Operating Margin
-729.19%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.